| CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206) | Medical College of Wisconsin | 2022-06-30 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL (NCT04030195) | Precision BioSciences, Inc. | 2020-03-24 |
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma (NCT04160195) | National Cancer Institute (NCI) | 2019-12-20 |
| Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia (NCT03755947) | Grupo Cooperativo de Hemopatías Malignas | 2018-12-01 |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies (NCT03151057) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-07-31 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878) | Oncternal Therapeutics, Inc | 2018-01-03 |
| Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL (NCT03502876) | French Innovative Leukemia Organisation | 2017-11-02 |
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT03204188) | National Heart, Lung, and Blood Institute (NHLBI) | 2017-09-22 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 (NCT03097770) | Chinese PLA General Hospital | 2017-04-01 |
| Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma (NCT03110640) | First Affiliated Hospital of Wenzhou Medical University | 2016-10-01 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (NCT02685670) | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 2016-02-01 |
| A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (NCT02336048) | Hoffmann-La Roche | 2015-06-26 |
| Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy (NCT02381080) | Janssen Research & Development, LLC | 2015-05-19 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT02168907) | Wake Forest University Health Sciences | 2014-12-01 |
| Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies (NCT02315118) | National University Hospital, Singapore | 2014-12-01 |
| B-Cell Hematologic Malignancy Vaccination Registry (NCT02298816) | Wake Forest University Health Sciences | 2014-08-01 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (NCT02213913) | University of Chicago | 2014-07-29 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy (NCT01735604) | Chinese PLA General Hospital | 2013-01-01 |
| Rituximab in Pretreated Elderly or Unfit B-CLL Patients (NCT01576588) | Prof. Dr. Med. Laimonas Griskevicius | 2011-10-01 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma (NCT02037256) | Barbara Ann Karmanos Cancer Institute | 2011-07-01 |
| Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia (NCT01982175) | Shanghai Zhangjiang Biotechnology Limited Company | 2011-07-01 |
| Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) (NCT01292135) | Pharmacyclics LLC. | 2011-02-01 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia (NCT01269385) | Mayo Clinic | 2011-01-01 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma (NCT01258998) | National Cancer Institute (NCI) | 2010-12-01 |
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL (NCT01217749) | Pharmacyclics LLC. | 2010-12-01 |
| Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) (NCT01212380) | Ohio State University Comprehensive Cancer Center | 2010-10-01 |
| Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) (NCT01144260) | CytRx | 2010-06-01 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01109069) | Pharmacyclics LLC. | 2010-06-01 |
| Safety of PCI-32765 in Chronic Lymphocytic Leukemia (NCT01105247) | Pharmacyclics LLC. | 2010-05-01 |
| Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia (NCT01126502) | National Cancer Institute (NCI) | 2010-05-01 |
| ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies (NCT01110473) | AbbVie (prior sponsor, Abbott) | 2010-04-01 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy (NCT01029366) | University of Pennsylvania | 2010-03-17 |
| Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen (NCT00918450) | Abbott | 2010-03-01 |
| Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia (NCT01649791) | Roswell Park Cancer Institute | 2010-01-01 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (NCT00867529) | Fred Hutchinson Cancer Center | 2009-02-01 |
| A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy (NCT00774345) | Celgene | 2009-01-27 |
| Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment (NCT00845104) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2009-01-01 |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies (NCT00697346) | Millennium Pharmaceuticals, Inc. | 2008-07-11 |
| Hydroxychloroquine in Untreated B-CLL Patients (NCT00771056) | Northwell Health | 2008-07-01 |
| Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia (NCT00646165) | Mundipharma Research Limited | 2008-07-01 |
| Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (NCT00648739) | Alexion Pharmaceuticals, Inc. | 2008-06-19 |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia (NCT00612612) | National Cancer Institute (NCI) | 2008-01-01 |
| Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00398112) | National Cancer Institute (NCI) | 2007-08-01 |
| Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma (NCT00621452) | Fred Hutchinson Cancer Center | 2007-08-01 |
| Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (NCT00485966) | Cylene Pharmaceuticals | 2007-06-01 |
| A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL (NCT00435084) | Valerio Therapeutics | 2007-02-01 |
| Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00377104) | National Cancer Institute (NCI) | 2006-09-01 |
| Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia (NCT00336206) | Tawam Hospital | 2006-07-01 |
| AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (NCT00321724) | National Cancer Institute (NCI) | 2006-05-01 |
| A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) (NCT00302861) | Genitope Corporation | 2006-03-01 |
| Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL (NCT00344786) | Biogen | 2006-02-01 |
| Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00290810) | National Cancer Institute (NCI) | 2005-12-01 |
| Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia (NCT00098371) | National Cancer Institute (NCI) | 2005-04-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia (NCT00098488) | National Cancer Institute (NCI) | 2005-04-01 |
| Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) (NCT00927797) | Heidelberg University | 2005-02-01 |
| Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) (NCT00147901) | German CLL Study Group | 2005-01-01 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT00101205) | National Cancer Institute (NCI) | 2004-11-01 |
| Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients (NCT00086580) | Genzyme, a Sanofi Company | 2004-07-01 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (NCT00089076) | National Cancer Institute (NCI) | 2004-06-01 |
| Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00119392) | Fred Hutchinson Cancer Center | 2004-06-01 |
| CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (NCT00290472) | National Cancer Institute (NCI) | 2004-03-01 |
| A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response (NCT00565981) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2004-03-01 |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy (NCT00800943) | Chronic Lymphocytic Leukemia Research Consortium | 2003-12-01 |
| Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients (NCT00254163) | US Oncology Research | 2003-12-01 |
| Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma (NCT00058240) | National Cancer Institute (NCI) | 2003-04-01 |
| Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia (NCT00046683) | Genzyme, a Sanofi Company | 2001-07-01 |
| Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia (NCT00006226) | National Cancer Institute (NCI) | 2000-09-01 |
| Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00005799) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia (NCT00003620) | National Cancer Institute (NCI) | 1999-06-01 |